APA (7th ed.) Citation

G, K., L, S., F, D., J, K., X, L., F, L., . . . SJ, K. (2025). A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(23), 4944. https://doi.org/10.1158/1078-0432.CCR-24-4280

Chicago Style (17th ed.) Citation

G, Ku, et al. "A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 31, no. 23 (2025): 4944. https://doi.org/10.1158/1078-0432.CCR-24-4280.

MLA (9th ed.) Citation

G, Ku, et al. "A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 31, no. 23, 2025, p. 4944, https://doi.org/10.1158/1078-0432.CCR-24-4280.